GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
- Status
- TERMINATED
- Phase
- PHASE1
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension
- Status
- COMPLETED
- Phase
- PHASE2
Fulvestrant 500mg in Patients With Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
- Status
- COMPLETED
- Phase
- PHASE2
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female Subjects
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)
- Status
- TERMINATED
- Phase
- PHASE1
Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
- Status
- COMPLETED
- Phase
- PHASE2